Posted by Michael Wonder on 21 Feb 2022
Drug funded for people with spinal muscular atrophy
15 February 2022 - The provincial government is covering costs for risdiplam, or Evrysdi, the medication used to treat a severe and rare neuromuscular disease.
The annual cost of risdiplam at list price ranges from $93,456 to $354,000, depending on the age and weight of the patient. British Columbia participated in pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer to finalise its funding decision.
